Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. Annals of surgical oncology Marincola Smith, P. n., Baechle, J. n., Tan, M. C., Solórzano, C. C., Lopez-Aguiar, A. G., Dillhoff, M. n., Beal, E. W., Poultsides, G. n., Cannon, J. G., Rocha, F. G., Crown, A. n., Cho, C. S., Beems, M. n., Winslow, E. R., Rendell, V. R., Krasnick, B. A., Fields, R. C., Maithel, S. K., Bailey, C. E., Idrees, K. n. 2020


Insurance status predicts access to medical care in the USA. Previous studies have shown uninsured patients with some malignancies have worse outcomes than insured patients. The impact of insurance status on patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is unclear.A retrospective cohort study of adult patients with resected GEP-NETs was performed using the US Neuroendocrine Tumor Study Group (USNETSG) database (2000-2016). Demographic and clinical factors were compared by insurance status. Patients =?65 years were excluded, as these patients are almost universally covered by Medicare. Kaplan-Meier and log-rank analyses were used for survival analysis. Logistic regression was used to assess factors associated with overall survival (OS).The USNETSG database included 2022 patients. Of those, 1425 were aged 18-64 years at index operation and were included in our analysis. Uninsured patients were more likely to have an emergent operation (7.9% versus 2.5%, p?=?0.01) and less likely to receive postoperative somatostatin analog therapy (1.6% versus 9.9%, p?=?0.03). OS at 1, 5, and 10 years was significantly higher for insured patients (96.3%, 88.2%, and 73.8%, respectively) than uninsured patients (87.7%, 71.9%, and 44.0%, respectively) (p?

View details for DOI 10.1245/s10434-020-08359-z

View details for PubMedID 32219725